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Interleukin-17 Stimulates STAT3-Mediated Endothelial Cell Activation for Neutrophil Recruitment

Introduction
Interleukin-17 (IL-17), mainly produced by CD4 T-helper 17 (Th17) cells, is a major pro-inflammatory cytokine that initiates and maintains inflammation [1, 2] . Besides Th17 cells, several other cells are capable of producing IL-17, including macrophages, dendritic cells, natural killer cells, natural killer T cells, lymphoid tissue inducer cells, and γδ-T cells. Previous studies in both mice and humans have shown that IL-17 plays a pivotal role in promoting multiple inflammatory diseases including rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), and cancer [3] [4] [5] [6] .
The broad impact of IL-17 is due to its ability to induce the chemotaxis and accumulation of inflammatory cells, such as neutrophils, to the sites of inflammation [7, 8] . However, IL-17 does not directly promote the chemotaxis of human neutrophils from peripheral blood [9] ; rather, it promotes the release of recruitment factors from the inflamed microenvironment. Recent studies demonstrate that IL-17 induces the production of IL-6, IL-8, Gro-α, G-CSF, and CCL20 in epithelial cells, synovial fibroblasts, colonic myofibroblasts, and airway smooth muscle cells [10] [11] [12] [13] [14] . Moreover, the induction of these inflammatory factors promotes recruitment and accumulation of inflammatory cells, such as neutrophils [15] .
In addition to inflammatory cells, endothelial cells play a crucial role in the inflammation process [16] . During acute and chronic inflammation, immune responses stimulate endothelial cell activation and induce angiogenesis [17] . Activated endothelial cells produce a series of adhesion factors, as well as cytokines and chemokines, to recruit inflammatory cells, such as neutrophils and monocytes [18] . Recently, the role of IL-17 in this process has been described in the context of tumorigenesis and rheumatoid arthritis [19] [20] [21] [22] . Some key mediators induced by IL-17 include: CXCR2, G-CSF, IL-6, VEGF, and PDGF. Thus, these data suggest that IL-17 promotes the activation of endothelial cells and the induction of angiogenesis. However, the molecular mechanisms underlying the function of IL-17 in these processes are still being defined.
The IL-17 family of cytokines contains six members: IL-17, IL-17B, IL-17C, IL-17D, IL-17F, and IL-25. IL-17 and IL-17F can form homo-or hetero-dimers that bind a heteromeric receptor complex containing IL-17RA and/or IL-17RC [2, 23, 24] . Binding of IL-17 to the IL-17 receptors typically leads to activation of the NF-κB, MAPKs, ERK, or C/EBPs signaling pathways [25] . Recently, Act1 was identified as an important mediator via its interaction with IL-17R through TRAF6-dependent and -independent downstream pathways [26] . In addition, IL-17-mediated activation of STAT3 has been reported in airway epithelial cells [27] and smooth muscle cells [23, 28] . However, the requirement of STAT3 in IL-17-activated endothelial cells has not been fully explored.
STAT3 is a member of the STAT family of proteins, which are important latent regulators during the inflammation process [29, 30] . Activation of STAT3 involves a tyrosine phosphorylation cascade involving recruitment by non-receptor tyrosine kinases including the JAK family (Tyk2, Jak1, 2, 3). Recruitment of STAT3 to the receptor kinase complex occurs via the interaction of its SH2 domain with a phosphorylated tyrosine residue at the receptor or kinase complex. STAT3 is then phosphorylated at a single tyrosine residue in the C-terminal domain, which leads to its dimerization, nuclear translocation, and ultimately the transcription of inflammatory factors [31] . Induction of inflammatory factors, including IL-8, has been linked to the regulation of STAT3 activation [32] . In addition, the differentiation and regulation of Th17 cells, macrophages, eosinophils, and neutrophils are also associated with STAT3 signaling. More importantly, STAT3 plays pivotal roles in the regulation of angiogenesis and endothelial cell activation [33] . Thus, STAT3 is a major mediator in regulating inflammation, immune cell development, and endothelial cell activation. Therefore, understanding the potential connection between IL-17 signaling and STAT3 activation in regulating endothelial cell activation will help to fully elucidate the molecular mechanisms of IL-17 in inflamed microenvironments.
In this study, we used a model of human endothelial cells to examine the function of STAT3 in IL-17-mediated endothelial cell regulation and inflammatory cell recruitment.
IL-17 induction leads to the activation of endothelial cell proliferation, migration, and tubule formation. In addition, IL-17 promoted the induction of GRO-α, GM-CSF, and IL-8 to regulate neutrophil recruitment, while silencing of STAT3 through siRNAs retarded these processes. Further investigations revealed that tyrosine phosphorylation of STAT3 play an important role in regulating this process. Mutation of the phosphorylation site Y705 directly attenuated STAT3 nuclear translocation and transcriptional activity in the presence of IL-17. In addition, a specific STAT3-Y705 inhibitor, FLLL31 [34] , reduced the expression of GM-CSF and IL-8, resulting in attenuation of neutrophil recruitment and endothelial cell activation. Further investigation identified that inhibition of IL-17RA reduced phosphorylation at Y705. Taken together, our results demonstrate the ability of IL-17 to regulate the production of inflammatory factors for neutrophil recruitment via the STAT3 signaling pathway.
Materials and Methods
Cell Culture HMEC is a human dermal microvascular endothelial cell line (HDMEC, Sciencell, Carlsbad, CA) and was cultured at 37°C, 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (FCS, HyClone, Logan, UT) and 100 units/ml Penicillin/Streptomycin. HL-60 cells are cultured in RPMI-1640 medium with 10% FCS, if not specified.
Materials
The JAK2 inhibitor, AG490, was purchased from Caliochem (Gibbstown, NJ). The STAT3 inhibitor, FLLL31, and other materials were purchased from Sigma-Aldrich Chemical (St. Louis, MO) unless specified otherwise. ELISA kits were purchased from eBioscience (San Diego, CA). Recombinant human IL-17, bFGF, and TNF-α were obtained from R&D Systems (Minneapolis, MN). Commercial SignalSilence® STAT3 siRNA and Control siRNA were purchased from Cell Signaling Technology (Beverly, MA).
Cell proliferation assay
The proliferation of HMECs was assessed with the Cell Counting Kit-8 (CCK-8, Dojindo, Kumomoto, Japan) according to the manufacturer's instructions. Briefly, HMECs were seeded into 96-well plates (1 × 10 4 cells/well), and following serum deprivation for 24 hours, then were stimulated with IL-17 (1-100 ng/ml) for 24 or 48 hours, respectively. TNF-α (10 ng/ml) was used as a positive control for proliferation induction. CCK-8 at a final concentration of 5 mg/ml was then added to the culture, and cell proliferation was measured 3 hours later using a microplate reader (OD value at 450 nm). Data are represented as relative fold increase over untreated control groups.
To examine the inhibitors of STAT3 signaling pathways, cells were pretreated with inhibitors of JAK2 (AG490) or STAT3 (FLLL31) for 1 hour prior to IL-17 treatment (50 ng/ml). Cell proliferation was measured 48 hours later using CCK-8 as described above.
Tubule formation assay
Tubule formation assays were conducted as previously described [35] . Briefly, 24-well plates were pre-coated with 100 μl/well matrigel for 1 hour at 37°C. HMECs were then seeded at 1 × 10 4 cells/well and incubated with bFGF (10 ng/ml) or different concentrations of IL-17. After 6 hours of incubation, cells were fixed and visualized by bright-field microscopy. Tubule formation images were captured with the Olympus DP1T digital camera system (Olympus Optical, Tokyo, Japan) and assessed in six randomly selected fields per well. To examine the functions of STAT3 signaling pathway inhibitors, the cells were pretreated with AG490 (10 μM) and FLLL31 (10 μM) for 1 hour before IL-17 treatment, and then examined as described above.
Migration assay
HMECs were plated into 12-well plates. After the cells formed a monolayer, a "wound" was created by scrapping a straight line into the bottom of the well with a p200 pipette tip. The wells were then washed in PBS and cultured in DMEM including IL-17 plus 2% FCS for 4 hours. Following this incubation, HMECs were 
Immunofluorescence labeling
HMECs were plated into 6-well plates and pre-treated with vehicle (0.1% DMSO), FLLL31 (10 μM), or AG490 (10 μM) for 30 minutes. The cells were then stimulated with IL-17 (50 ng/ml) for 1 hour. Treated cells were washed with ice-cold PBS, fixed with cold methanol, and cultured in blocking buffer for 30 minutes. Following blocking, the cells were washed with PBS and cultured with an anti-STAT3 monoclonal antibody (Cell Signaling Technology) overnight at 4°C. After washing, the cells were labeled with a FITC-conjugated anti-mouse secondary antibody, stained with DAPI, and viewed with a scanning confocal imaging system. Six random fields in each well (magnification × 60, Leica DMI 6000B-CS) were chosen for analysis.
To examine the nuclear translocation of STAT3 and its dominant-negative mutants after IL-17 treatment, the GFP-fused wild type and Y705F mutants of STAT3 were transfected for 24 hours into HMECs with Lipofectin according to the manufacturer's instructions. Then HMECs were treated with IL-17 (50 ng/ ml) for 2 hours. The cells were viewed by fluorescence confocal microscopy and six random fields in each well were counted.
Western blotting analysis of STAT3 translocation into nuclei
HMECs were serum-starved in DMEM for 24 hours and then treated with IL-17 (50 ng/ml) for 0.5-2 hours. Cytosolic and nuclear proteins were then obtained using the nuclear-cytosol extraction kit (Applygen, Beijing) with a protease inhibitor cocktail (Roche), according to the manufacturer's instructions. Equal amounts of protein from individual samples were resolved by electrophoresis in a SDS polyacrylamide gel, and gel slices were then transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA). The membranes were washed with Tris-buffered saline plus 0.1% Tween-20 (TBST), and then blocked with 5% nonfat milk for 1 hour at room temperature. The membranes were then probed with anti-phosphoTyr705 (Y705), anti-phospho-Ser727 (S727) of STAT3, and anti-STAT3 monoclonal antibodies overnight at 4°C (Cell Signaling Technology). Lamin B and β-actin antibodies were used to indicate nuclear and cytosolic protein controls, respectively. Following overnight incubation, membranes were washed extensively with TBST and developed by chemiluminescence detection with a LAS3000-mini image analysis system.
RNA interference assay
HMECs were transfected with inference siRNAs targeting STAT3, IL-17RA, or IL-17RC with GenoFect transfection reagents (Genobio, Beijing, China) for 24 hours according to the manufacturer's instructions. The cells were then cultured in the presence of IL-17 (50 ng/ml) and collected at the time points indicated. Commercial SignalSilence® STAT3 siRNA and Control siRNA were purchased from Cell Signaling Technology. Specific 27mer siRNA duplexes targeting IL-17RA and IL-17RC were purchased from OriGene Technologies (Rockville, MD). The duplex sequences are as following:
IL-17RA: rGrGrGrArUrArCrCrArArGrArUrArArArUrUrGrCrArUrGCG IL-17RC: rCrUrCrArArArGrArCrGrArUrGrUrGrCrUrArCrUrGrUrUrGG
STAT3 luciferase activity assay
The construction of the STAT3 recognition promoter motif in the pGL6 vector was previously described [36, 37] . Stably transfected HMEC cells were treated with IL-17 with or without chemical inhibitors in serum-free medium for 4 hours. The cells were then harvested and lysed according to the luciferase reporter assay kit protocol (Promega, Madison, WI). Cell lysates were measured using a luminometer (Promega) according to the manufacturer's instructions. Relative luciferase activities were normalized to those of untreated control groups.
Neutrophils and endothelial cell adhesion assay
Isolations of human neutrophils from whole blood were performed with solution of Polymorphprep® according to the manufacturer's instructions (AXIS-SHIELD, Oslo, Norway). The final centrifugation of isolated human neutrophils was adjusted to 2 × 10 6 /ml. The neutrophils were then added above the HMEC /well) and added above the HMEC monolayer for 2 hours. Next, the supernatants and unbound neutrophils were discarded, and HMECs were washed with PBS and dissolved in DMSO for 10 minutes. The OD value at 570 nm was then assessed using a microplate reader (BioTek, Winooski, VT). Adhesion activities are indicated as the relative OD 570 difference of IL-17-treated cells with that of untreated controls.
Adhesion assays of HL-60 cells were performed using the method described above. Briefly, HMEC cells were seeded into 96-well plates and pre-incubated with or without FLLL31 or AG490 for 30 minutes followed by treatment with IL-17 (50 ng/ml) for 6 hours. Then, HL-60 cells pre-labeled with MTT (1 × 10 6 / ml) were added to the medium of HMECs for 2 hours, and the OD value at 570 nm was measured.
HL-60 chemotaxis and transmigration assay
Transwell chemotaxis assays were carried out to assess HL-60 recruitment to endothelial cells using the 3-μm Millicell inserts (Millipore) [38] . Briefly, HMECs were seeded into 24-well plates and grown until confluent. The cells were then pre-incubated with or without FLLL31 or AG490 for 30 minutes, and then treated with IL-17 (50 ng/ml) for 6 hours. HL-60 cells stained with CellTracker Green (2 × 10 6 /ml) were then added to the top chambers above the HMEC monolayer, and allowed to migrate. After 2 hours, the cells under the chambers were fixed with 4% formaldehyde in PBS for 15 minutes. HL-60 cells that had migrated to the bottom chamber of HMECs were viewed by fluorescence confocal microscopy. Five random fields in each well were selected for analysis.
Human Cytokine Antibody Array Chip Assay
HMECs were serum-starved overnight, then cultured in the presence of IL-17 (50 ng/ml) for 24 hours. The culture medium was collected and centrifuged at 12,000 g for 10 min. Inflammatory factors in the supernatant were then analyzed using a Cytokine Antibody Array Chip (Cat: AAH-CYT-3-8, RayBio), according to the manufacturer's instructions. Analysis was performed in triplicate. Data are represented as the fold increase of IL-17-treated groups over control groups.
Statistical analysis
Statistical significance was analyzed using the student's t-test. P values < 0.05 were considered statistically significant. All data are representative of at least three separate experiments.
Results
IL-17 promotes endothelial cell activation in vitro
First, we examined whether IL-17 promoted the proliferation of endothelial cells. HMECs were treated in vitro with different concentrations of IL-17 and the Cell Counting Kit-8 was used to assess proliferation rate. After treatment for 24 or 48 hours, IL-17 promoted endothelial cell proliferation in a concentration-dependent manner (Fig. 1A) . Compared with the untreated control group, concentrations of both 50 and 100 ng/ml IL-17 treatment significantly promoted endothelial cell proliferation (P<0.01).
Next, we examined the ability of IL-17 to induce tubule formation on endothelial cells grown in vitro. HMECs were cultured on Matrigel and treated with IL-17 for 6 hours, after which tubule formation was subsequently captured and assessed. Similar to the positive control (10% FCS), IL-17 significantly promoted endothelial tubule formation in HMECs (Fig. 1B and 1C) . The observed increase of tubule formation indicated that IL-17 activation might also increase HMEC migration. Therefore we used a "wound healing assay" to assess HMEC migration. HMECs monolayers were disrupted using a pipette tip to create a "wound". The migration of HMECs into the "wound" was then assessed 4 hours later. Results showed that IL-17 promoted the migration of HMECs in a concentration-dependent manner (Fig. 1D  and 1E ). In addition, pre-treating HMECs with an IL-17R blocking antibody prevented IL-
17-mediated migration (Data not shown)
. These data confirmed that IL-17 promotes HMEC migration. Collectively, these data support the role of IL-17 in promoting endothelial cell activation.
IL-17 promotes endothelial cell production of inflammatory factors to recruit neutrophils
Since endothelial cells can promote the recruitment of neutrophils to sites of inflammation, we investigated whether IL-17 promotes neutrophil recruitment to HMECs. Niggli and colleagues reported that differentiated HL-60 cells, a human neutrophil cell line, were valid for investigating neutrophil migration and chemotaxis [39] . The results showed that there were little differences between differentiated HL-60 cells and human neutrophils with A. HMECs were stimulated with IL-17 (10, 50, 100 ng/ml) for 24 or 48 hours, at which point proliferation was assessed using the Cell Counting Kit-8. TNF-α (10 ng/ml) was used as a positive control. Data are represented as the relative fold induction over untreated control groups. *, P < 0.05 vs. Control; **, P < 0.01 vs. Control; ***, P < 0.001 vs. Control. B. HMECs were plated in Matrigel and treated with 10% FCS, bFGF (10 ng/ml), IL-17 (10 and 50 ng/ml). Tubule formation was assessed in six randomly selected fields per well, and the images were captured with the Olympus DP1T digital camera system (Olympus Optical). C. Tubule images were captured, and lengths were assessed from six randomly selected fields per well. *, P < 0.05 vs. Control group; **, P < 0.01 vs. Control; ***, P < 0.001 vs. Control. D. Following exposure to IL-17, HMECs were fixed in 1% gluteraldehyde, stained with 0.1% crystal violet, and viewed by light microscopy (magnification × 20). FCS (10%) treatment as the positive control. The images were captured from six randomly selected fields per well. E. Relative migratory activities of the different groups were calculated by the scraped width difference of endothelial cells per well compared with that of the untreated control group. The images were captured from six randomly selected fields per well.
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Cellular Physiology and Biochemistry addition, treatment of IL-17 elevated the phosphorylation and activation of ERK and p38 at the early time points treatment, while no significant changes were observed in later time points, as previously reported [40] . Next, the immunofluorescence analysis revealed that IL-17 induced STAT3 nuclear translocation (Fig. 3B) . Comparatively, STAT3 in untreated groups was almost located exclusively in the cytosol. To further confirm the role of IL-17, HMECs were pre-treated with an IL-17R blocking antibody. Results showed that the nuclear translocation of STAT3 was blocked by anti-IL-17R antibody pre-treatment. Further western blot analysis revealed that IL-17 promoted the tyrosine phosphorylation of STAT3 both in the cytosolic and nuclear fractions. However, serine phosphorylation was only detected at significant levels in the nuclear fractions (Fig. 3C) . These results confirm that IL-17 promotes the activation of STAT3 in endothelial cells.
To further evaluate the role of STAT3 in this process, we used siRNAs to attenuate the expression of STAT3 in HMECs. Western blotting analysis revealed that commercial siRNAs against STAT3 significantly attenuated the protein expression level of STAT3, including tyrosine phosphorylation of STAT3 following IL-17 treatment (Fig. 3D) . In addition, knockdown of STAT3 decreased the expression of Gro-α, GM-CSF, and IL-8 following exposure to IL-17 (Fig. 3E) . Interestingly, these results indicated STAT3 might regulate the induction of Gro-α, GM-CSF, and IL-8.
Phosphorylation of STAT3 705 tyrosine plays an important role in IL-17-induced endothelial cell activation
Given that IL-17 promoted the phosphorylation and nuclear translocation of STAT3, we next investigated mechanisms of STAT3 activation in this process. We mutated the major tyrosine 705 phosphorylation site of STAT3 and constructed GFP-fused dominant-negative mutants (Y705F). Next, the dominant-negative mutants were transfected into HMECs and treated with IL-17. Immunofluorescent imaging revealed that after IL-17 treatment, nuclear translocation of STAT3 was blocked in the Y705F mutant-transfected HMECs (Fig. 4A) . These results confirmed that the Y705F mutant retarded the tyrosine phosphorylation of STAT3, and attenuated its translocation to the nuclei. Since nuclei-associated STAT3 modulates the transcription and expression of target genes, we sought to establish whether these phosphorylation sites were important for IL-17-mediated STAT3 activation. Therefore, we fused a luciferase reporter plasmid to a STAT3 recognition motif, transfected the recombinant plasmid into HMECs, and measured the effect of IL-17 treatment on STAT3 regulation of the reporter gene. Consistent with our immunofluorescence analysis, IL-17 treatment elevated the luciferase activity of STAT3 compared to the untreated controls. As expected, the Y705F mutation prevented IL-17-induced transcriptional activity of STAT3 in HMECs (Fig. 4B) . Therefore, these results indicate that phosphorylation of Y705 is necessary for IL-17-mediated STAT3 activation in HMECs.
To further evaluate the role of Y705 in IL-17-mediated endothelial cell activation, the specific inhibitor of tyrosine phosphorylation of STAT3 was used to investigate the function of IL-17 in HMECs. FLLL31 is a newly developed STAT3 inhibitor which selectively binds to Janus kinase 2 (JAK2) and the STAT3 Src homology-2 (SH2) domain, and specifically suppresses the Y705 phosphorylation of STAT3. Our results showed that in the presence of FLLL31, the proliferation function induced by IL-17 was attenuated (Fig. 4C) . To further evaluate the role of tyrosine phosphorylation of Y705 in the promotion of endothelial cell activation, we examined the effects of FLLL31 on tubule formation. As shown in Fig. 4D and 4E, FLLL31 attenuated IL-17-mediated tubule formation in matrigel. These results further indicate that STAT3 is an important regulator in IL-17-mediated endothelial cell activation, and that phosphorylation of STAT3 at Y705 plays an important role in this process.
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Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry endothelial cells to produce inflammatory factors, which play vital roles in the recruitment of neutrophils. Also, these data suggest that tyrosine phosphorylation at Y705 in STAT3 is necessary for IL-17-mediated neutrophil recruitment by endothelial cells.
IL-17-mediated STAT3 activation mainly occurs through IL-17RA
Given that IL-17RA is the major receptor of IL-17, we wondered whether tyrosine phosphorylation of STAT3 is relative to IL-17RA. We then silenced IL-17RA in HMECs with a specific siRNA. Knockdown of IL-17RA attenuated the activation of Y705 phosphorylation on STAT3 (Fig. 6A) . In addition, pre-treatment of IL-17RA monoclonal antibodies inhibited the tyrosine phosphorylation of STAT3 upon IL-17 treatment (Data not shown). Thus, the modulation of STAT3 is linked to IL-17RA. Next, we investigated the transcriptional activity of STAT3 after silencing IL-17RA in HMECs. As expected, silencing of IL-17RA prevented IL-17-induced transcriptional activity of STAT3 in HMECs (Fig. 6B) . Moreover, silencing of IL-17RA significantly reduced the release of GRO-α, GM-CSF, and IL-8 by HMECs (Fig. 6C) . Therefore, our results support that IL-17, through IL-17RA, can regulate the STAT3 signaling Fig. 6 . IL-17RA is the major receptor promoting STAT3 regulation in endothelial cells. A. HMECs were transfected with siRNAs targeting IL-17RA or a random sequence for 24 hours, and then treated with IL-17 (50 ng/ml) for 4 hours. Then, cells were collected and analyzed by western blot using IL-17RA, p-STAT3 (Y705), pERK, and pP38 monoclonal antibodies. The blots were also probed with anti-β-actin antibodies as an internal control. Fold indicates the calculated relative intensity of target protein/β-actin by densitometry. B. HMECs stably expressing STAT3 Luciferase were transfected with siRNAs targeting IL-17RA or a random sequence for 24 hours. The cells were then treated with IL-17 (50 ng/ml) for 4 hours and luciferase activity was measured. *, P < 0.05 vs. Control; N.S.= Not Significant (P > 0.05 vs. siIL-17RA alone). C. HMECs were transfected with siRNAs targeting IL-17RA or a random sequence for 24 hours, and then treated with IL-17 (50 ng/ml) for 12 hours. The culture medium was then collected and ELISA kits were used to examine the levels of GRO-α, GM-CSF, and IL-8. ***, P < 0.001 vs. Control; ###, P < 0.001 vs. IL-17 treatment group. D. An abbreviated cartoon of the signaling pathway. IL-17 promotes the activation of the JAK-STAT3 pathway via IL-17RA, resulting in phosphorylation of tyrosine at position Tyr-705 (Y705) and nuclear translocation of STAT3. Activated endothelial cells produce the pro-inflammatory chemokines and cytokines, including Gro-α, IL-8, and GM-CSF, which, in turn, promote neutrophil recruitment and adhesion to endothelial cells. Yuan 
pathway and the production of inflammatory factors, which might play important roles in the recruitment of neutrophils.
Discussion
In this study, we investigated the function and molecular mechanisms of IL-17-mediated endothelial cell activation and neutrophil recruitment. Our results indicate that IL-17 directly activated endothelial cells through promoting proliferation, migration, and tubule formation. In addition, IL-17 promoted the secretion of the neutrophil recruitment factors GRO-α, GM-CSF, and IL-8 from HMECs, which enhanced the adhesion and neutrophil recruitment to HMECs. Further experiments showed that these processes were directly correlated with to STAT3 regulation in HMECs. IL-17 promoted phosphorylation and nuclear translocation of STAT3, while silencing of STAT3 by RNA interference significantly attenuated IL-17-mediated endothelial cell activation, inflammatory factors secretion, and neutrophil recruitment. Moreover, tyrosine phosphorylation on Y705 was important for STAT3 regulation following IL-17 activation. Our results showed that dominant-negative mutant and specific inhibitors of Y705 phosphorylation attenuated the function of IL-17 in HMECs. Furthermore, phosphorylation of Y705 could be partly attributed to the IL-17RA transducing signal, since phosphorylation of Y705 could be inhibited by interference of IL-17RA. Based on these observations, we conclude that IL-17 promotes activation of endothelial cells through the STAT3 signaling pathway, which in turn enhances neutrophil recruitment (Fig. 6D) .
In the present study, IL-17 directly promoted endothelial cell activation via migration and tubule formation. These results are consistent with previous observations using other endothelial cell lines [41] [42] [43] . IL-17 also promoted the proliferation of endothelial cells in a dose-dependent manner (P<0.05), with higher doses of IL-17 increasing proliferation by approximately 50%. Moreover, our data confirmed the effects of endothelial cells response to IL-17 on adhesion regulation and inflammatory cells recruitment. Although expression of adhesion molecules on HMECs was not examined during our investigations, ICAM-1 induction in response to IL-17 has been previously reported [11] . In addition, pre-treating HMECs with IL-17R blocking antibodies significantly attenuated IL-17-mediated HMEC activation. Collectively, these results establish IL-17 as an endothelial cell activation stimulus. Moreover, our data confirmed the effects of IL-17 on endothelial cells for inflammatory cell recruitment during the inflammation process.
Neutrophils are inflammatory cells believed to be the first-line defenders against pathogens. Neutrophil recruitment and adhesion to endothelial cells has been investigated in inflammatory diseases such as RA, COPD, and cancer [44] . One essential role of endothelial cells during the inflammatory process is coordinating the recruitment of inflammatory cells, including neutrophils, monocytes, and lymphocytes into underlying tissues, and actively participating in neovascularization processes [45, 46] . Previous results have identified IL-17 as an important mediator of neutrophilic inflammation [47] . However, neutrophils do not respond directly to IL-17, which suggests that other structural cells, such as endothelial and epithelial cells, might be involved in IL-17-mediated neutrophil recruitment. Although previous reports have indicated that IL-17 can promote the activity of epithelial cells and fibroblasts, and induce smooth muscle cells to recruit neutrophils, the effect and relative mechanism of IL-17 on endothelial cells remains poorly investigated. Our studies reveal that IL-17 activated endothelial cells through STAT3 regulation, promoted the induction of GRO-α, GM-CSF, and IL-8, and augmented the recruitment and accumulation of neutrophils. The requirement for STAT3 was established through the use of FLLL31, which is a specific inhibitor of STAT3. Furthermore, siRNA silencing of STAT3 significantly inhibited the induction of inflammatory factors. Therefore, this study reveals a molecular mechanism by which IL-17 mediates neutrophil recruitment through activating endothelial cells via the STAT3 pathway.
Multiple inflammation regulation pathways, including the PI3K/Akt, Act1/TRAF6/ NFκB, and MAPK/ERK signaling pathways have all been associated with IL-17-mediated downstream signaling pathways in different kinds of cells [2] . The induction of these various signaling cascades might be cell-type specific, IL-17 concentration-dependent, or associated with particular target genes. Moreover, since IL-17 can bind IL-17 receptor complexes as a homo-or hetero-dimer, the downstream signaling cascades may be regulated through IL-17RA and/or IL-17RC [8, 23, 48] . Herein, we demonstrate that IL-17 promotes the phosphorylation and nuclear translocation of STAT3 in HMECs. The IL-17-induced activation of STAT3 could be linked to the release of GRO-α, GM-CSF, and IL-8. Activation of STAT3 might function as the downstream regulator of IL-17RA, since we also observed that silencing IL-17RA could inhibit the tyrosine phosphorylation of STAT3 and reduce the expression of GRO-α, GM-CSF, and IL-8. Importantly, the expression levels of IL-8 and GM-CSF were directly attenuated upon STAT3 inhibition and siRNA silencing, which indicated that the release of these pro-inflammatory cytokines may be directly mediated by STAT3, or indirectly via other transcription factors such as NFκB or C/EBPβ [49] . However, expression levels of GRO-α were only partly inhibited under the same conditions. These data imply that the regulation of GRO-α may be induced by alternative molecular mechanisms. Together, these data suggest that STAT3 downstream of IL-17RA may be a major mediator of IL-17-mediated activation of endothelial cells. Further investigations on the role of nuclei-associated STAT3 in endothelial cells will provide the detailed mechanism of the regulation of inflammatory factors and chemokine production.
Differences in expression levels of IL-17 receptors, stimulated concentrations of IL-17, and treatment times in endothelial cells may all contribute to the signaling cascades involved. Although we did not observe significant attenuation of IL-17-induced endothelial cell proliferation in the presence of ERK or PI3K inhibitors, respectively (Data not shown), our observations have not excluded the potential involvement of these signaling pathways. For example, the activation of STAT3 can be regulated through the ERK and PI3K pathways [29] . Our data reveal that the phosphorylation of ERK and p38 were also inhibited after silencing of IL-17RA. ERK might play roles in regulation of STAT3 tyrosine phosphorylation in endothelial cells through an alternative mechanism or through other receptors of IL-17. Interestingly, we observed that STAT3 transcriptional activity was blocked by PI3K inhibition. Since STAT3 is a downstream regulator of PI3K [48, 50] , and IL-17 has been reported to activate endothelial cells through PI3K, our observations therefore elucidate the potential role of STAT3 in the regulation of IL-17 in endothelial cells as the mediator of PI3K signals.
FLLL31 is a newly developed STAT3 inhibitor which specifically suppresses the Y705 phosphorylation of STAT3 [34] . Previously, we identified that FLLL31 specifically inhibited STAT3 phosphorylation, attenuated LPS-stimulated NO, and reduced inflammatory factor production in macrophages. In addition, FLLL31 inhibited the proliferation and lymphoblastic transformation of lymphocytes. Moreover, FLLL31 significantly attenuated recruitment of inflammatory cells and mucus hypersecretion in DRA-challenged murine lung sections. Importantly, FLLL31 reduced the expression of IL-17 and Ly-6G/Gr-1 + cells in DRA-challenged murine lungs [51] . Meanwhile, we observed that FLLL31 reduced the expression of CD31 in the lung sections (Data not shown), which is consistent with the observations that IL-17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease in K14-IL-17A(ind/+) mice [18] . Taken together, these data further suggest that inhibition of Y705 on STAT3 could attenuate the endothelial cell activation and recruitment of neutrophils in vivo.
In addition, other mediators of endothelial cell function might be involved in regulating IL-17 signals. HMEC is a JAK3 hyperactivation endothelial cell line, and phosphorylation of JAK3 increased upon IL-17 treatment in HMECs (Data not shown). Therefore, investigations on JAK3 expression and STAT3 regulation might further elucidate the molecular mechanism of IL-17 in HMECs. Moreover, accumulating evidence suggests that the late Y705 phosphorylation of STAT3 is induced by IL-6 release upon GPCR activation [52] . Activation of GPCRs is frequently linked to the modulation of various transcriptional factors including [53] , which plays an important role in hematopoietic development and immune regulation. It is therefore plausible that IL-17 may modulate indirect functions through GPCRmediated STAT3 activation. For example, Gro-α and IL-8 can both promote endothelial cell activation through the chemokine receptor CXCR2 in an autocrine loop [54] , and previous investigations have reported that IL-17 promotes angiogenesis through CXCR2 [55] . Thus, the potential autocrine feedback between CXCR2 and IL-17 in mediating STAT3 activation will be an interestingly area of future study. Overall, this study demonstrates that STAT3 acts as a link between IL-17-mediated endothelial cell activation and neutrophil recruitment, and is important for the release of GRO-α, GM-CSF, and IL-8 from endothelial cells stimulated by IL-17. 
